Individual trigger factors for hemorrhagic stroke: Evidence from case-crossover and self-controlled case series studies
J Liu, C Luo, Y Guo, F Cao, J Yan - European Stroke Journal, 2023 - journals.sagepub.com
Background: Hemorrhagic stroke (HS) is a sudden-onset disease with high mortality and
disability rates, and it is crucial to explore the triggers of HS. In this study, we analyzed …
disability rates, and it is crucial to explore the triggers of HS. In this study, we analyzed …
Comparative risk of arterial thromboembolic events between aflibercept and ranibizumab in patients with maculopathy: A population-based retrospective cohort study
Background The increasing numbers of elderly patients and rising incidence of maculopathy
raise concerns over arterial thromboembolic events (ATEs) with the use of intravitreal anti …
raise concerns over arterial thromboembolic events (ATEs) with the use of intravitreal anti …
Assessing intravitreal anti-VEGF drug safety using real-world data: methodological challenges in observational research
G Scondotto, S Crisafulli, IC Antonazzo… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction It is generally acknowledged that the ocular safety profile of intravitreal anti-
VEGF drugs is acceptable, while the burden of systemic safety of these intravitreal agents is …
VEGF drugs is acceptable, while the burden of systemic safety of these intravitreal agents is …
Risk analysis for patients with arterial thromboembolic events after intravitreal ranibizumab or aflibercept injections
YI Chou, HY Chang, MY Lin, CH Tseng, TJ Wang… - Scientific Reports, 2023 - nature.com
Intravitreal anti–vascular endothelial growth factor (anti-VEGF) agents have been
increasingly applied in the treatment of retinal neovascular diseases. Concerns have arisen …
increasingly applied in the treatment of retinal neovascular diseases. Concerns have arisen …
Effect modification by indication to the risks of major thromboembolic adverse events in patients receiving intravitreal anti-vascular endothelial growth factor treatment …
Background The association between intravitreal anti-vascular endothelial growth factor
(anti-VEGF) treatment and the risk of major thromboembolic adverse events (TAEs) remains …
(anti-VEGF) treatment and the risk of major thromboembolic adverse events (TAEs) remains …
Risk of myocardial infarction, stroke, or death in new users of intravitreal aflibercept versus ranibizumab: a nationwide cohort study
S Billioti de Gage, M Bertrand, S Grimaldi… - Ophthalmology and …, 2022 - Springer
Introduction The risk of thromboembolic events or death in patients treated with intravitreal
anti-vascular endothelial growth factor (IVT anti-VEGF) is poorly described on a large scale …
anti-vascular endothelial growth factor (IVT anti-VEGF) is poorly described on a large scale …
Farmacoterapia e evolução clínica de pacientes com degeneração macular relacionada à idade em tratamento com Ranibizumabe
JGB Lima, DSOG Lima… - … A LAS CIENCIAS …, 2024 - ojs.revistacontribuciones.com
A degeneração macular relacionada à idade (DMRI) é uma das maiores causas de
cegueira em pessoas com mais de 55 anos nos países industrializados. Está relacionada …
cegueira em pessoas com mais de 55 anos nos países industrializados. Está relacionada …
Liposome formulations
A Santos, P Frost - US Patent 11,712,419, 2023 - Google Patents
The present invention relates to pharmaceutical formulations comprising an anti angiogenic
compound such as a monoclonal antibody or fragment thereof selected from, for example …
compound such as a monoclonal antibody or fragment thereof selected from, for example …
Liposome formulations
A Santos, P Frost, J Hsiao - US Patent 11,458,199, 2022 - Google Patents
The present invention relates to pharmaceutical formulations comprising an anti angiogenic
compound such as a monoclonal antibody or fragment thereof selected from, for example …
compound such as a monoclonal antibody or fragment thereof selected from, for example …